On the stock market since 1994, it operates in the world of health and science. It has 108 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 44% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly above the class average — a step short of the very top.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades 49% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 31% a year on average.
Sales run at $103.1M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 17 buys and 16 sells. Management buying with its own money is usually read as a good sign.
A loss of $37.6M against $103.1M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, SMTI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SMTI is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.